Kiniksa (KNSA) shifts from survival to growth as Arcalyst nears blockbuster sales and pipeline KPL-387 readouts loom—get the ...
The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple ...
Nirsevimab may offer infants stronger protection against severe respiratory syncytial virus than maternal vaccination, ...
Everyday Health on MSN
How to plan for successful home SCIg self-administration for primary immunodeficiency
Learn how to self-administer SCIg at home for primary immunodeficiency. Tips on preparation, reducing pain, managing ...
In the treatment of inflammatory bowel disease, synthetic mucus gels can be used to deliver monoclonal antibodies without inducing broad immunosuppression.
As deaths rose and treatments failed, morale among healthcare workers was at an all-time low. During that time, Dr. David Thrasher received a call from an Eli Lilly executive announcing emergency use ...
Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or ...
Before Jackson took office at ARPA-H, the agency’s chief data officer departed after disagreeing with the administration’s ...
AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...
SurvivorNet on MSN
Cancer patients are living longer — a closer look at the treatments driving this progress
New data show cancer survival has reached a record high — nearly 70% of patients now live at least five years after diagnosis ...
Preliminary total global full year 2025 revenue of approximately $616 millionPreliminary BRIUMVI U.S. fourth quarter and full year 2025 net ...
Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains the critical challenges of developing bispecific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results